What went wrong for 23andMe
Biotech company 23andMe had a rough 2024, including a $30 million settlement payment after customer data was compromised.
Kepler Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)
In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
GSK remains steady Friday, still outperforms market
GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...
GSK falls Thursday, underperforms market
Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...
Wayne biotech firm received $67.5 million investment to test gene therapy for heart disease
The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
In a report released today, James Gordon from J.P. Morgan reiterated a Sell rating on GlaxoSmithKline (GSK – Research Report). The company’s ...